论文部分内容阅读
卵巢癌是妇科最常见的恶性肿瘤之一,迄今由于其缺乏完善的早期诊断方法,其死亡率居妇科恶性肿瘤的首位,成为妇科恶性肿瘤威胁最大的疾病。化疗是治疗卵巢癌的主要辅助手段,其机制主要是抑制肿瘤细胞生长和促进肿瘤细胞凋亡。但肿瘤细胞对化疗药物产生耐药严重制约了抗肿瘤药物效能的发挥,晚期病人的5年生存率为25%～30%,是卵巢癌治疗失败的主要原因之一。近年随着分子生物学及其研究方法的飞速发展,p53基因在卵巢癌研究中日趋深入,其结构改变及功能异常可能与卵巢癌耐药有关。本文就p53基因与卵巢癌耐药关系的研究现状作一扼要综述。
Ovarian cancer is one of the most common malignant tumors in gynecology. So far, its mortality rate ranks first in gynecological malignant tumors due to its lack of perfect early diagnosis, which has become the most serious threat to gynecologic malignancies. Chemotherapy is the main adjuvant treatment of ovarian cancer, the mechanism is mainly to inhibit tumor cell growth and promote tumor cell apoptosis. However, the resistance of tumor cells to chemotherapeutic drugs severely restricts the exertion of antitumor drug efficacy. The 5-year survival rate of advanced patients is 25% -30%, which is one of the main reasons for the failure of ovarian cancer treatment. In recent years, with the rapid development of molecular biology and its research methods, p53 gene in ovarian cancer research increasingly in-depth, its structural changes and dysfunction may be related to drug resistance of ovarian cancer. This review summarizes the research status of p53 gene and drug resistance in ovarian cancer.